Roivant Sciences (NASDAQ:ROIV) Insider Mayukh Sukhatme Sells 339,441 Shares

Roivant Sciences Ltd. (NASDAQ:ROIV) insider Mayukh Sukhatme sold 339,441 shares of Roivant Sciences stock in a transaction on Monday, February 9th. The stock was sold at an average price of $26.47, for a total transaction of $8,985,003.27. Following the sale, the insider owned 19,148,664 shares in the company, valued at $506,865,136.08. This represents a 1.74% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Mayukh Sukhatme also recently made the following trade(s):

• On Monday, December 29th, Mayukh Sukhatme sold 311,873 shares of Roivant Sciences stock. The shares were sold at an average price of $21.74, for a total transaction of $6,780,119.02.
• On Wednesday, December 31st, Mayukh Sukhatme sold 1,018,995 shares of Roivant Sciences stock. The stock was sold at an average price of $21.71, for a total transaction of $22,122,381.45.
• On Wednesday, December 17th, Mayukh Sukhatme sold 26,831 shares of Roivant Sciences stock. The shares were sold at an average price of $23.09, for a total transaction of $619,527.79.

Roivant Sciences Stock Down 2.0%

NASDAQ:ROIV opened at $26.80 on Thursday. Roivant Sciences Ltd. has a 12-month low of $8.73 and a 12-month high of $27.94. The firm has a market capitalization of $18.64 billion, a PE ratio of -22.91 and a beta of 1.22. The firm has a 50-day moving average price of $22.49 and a 200 day moving average price of $18.14.

Analysts Set New Price Targets

Several analysts recently commented on ROIV shares. Leerink Partners boosted their price target on Roivant Sciences from $29.00 to $32.00 and gave the company an “outperform” rating in a research note on Monday, December 15th. Weiss Ratings downgraded shares of Roivant Sciences from a “hold (c-)” rating to a “sell (d)” rating in a research note on Monday. TD Cowen reiterated a “buy” rating on shares of Roivant Sciences in a research report on Saturday, February 7th. Wall Street Zen upgraded shares of Roivant Sciences from a “strong sell” rating to a “hold” rating in a research report on Sunday, November 16th. Finally, Citigroup raised their price objective on shares of Roivant Sciences from $26.00 to $35.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Roivant Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $28.69.

Institutional Trading of Roivant Sciences

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. SBI Securities Co. Ltd. lifted its holdings in Roivant Sciences by 1,740.3% during the 4th quarter. SBI Securities Co. Ltd. now owns 1,233 shares of the company’s stock worth $27,000 after buying an additional 1,166 shares in the last quarter. Jones Financial Companies Lllp raised its position in shares of Roivant Sciences by 226.0% during the third quarter. Jones Financial Companies Lllp now owns 1,656 shares of the company’s stock worth $25,000 after acquiring an additional 1,148 shares during the last quarter. Allworth Financial LP lifted its stake in shares of Roivant Sciences by 48.1% during the third quarter. Allworth Financial LP now owns 1,795 shares of the company’s stock valued at $27,000 after acquiring an additional 583 shares during the period. Bessemer Group Inc. lifted its stake in shares of Roivant Sciences by 41.5% during the third quarter. Bessemer Group Inc. now owns 1,852 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Finally, Clearstead Advisors LLC boosted its holdings in Roivant Sciences by 141.6% in the fourth quarter. Clearstead Advisors LLC now owns 2,907 shares of the company’s stock valued at $63,000 after acquiring an additional 1,704 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Roivant Sciences Company Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.